Quantitative Unified Assessment of Novel Triplet Therapy and Unconventional Maintenance With Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise from concurrently targeting androgen receptor signaling pathways and bone metastases.

Start Date01 Sep 2026

Sponsor / Collaborator

Mfar Constructions Pvt Ltd.

[+1]

CTIS2025-524208-31-00

/ Not yet recruitingPhase 2

Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.

Start Date02 Apr 2026

Sponsor / Collaborator

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

NL-OMON57275

/ RecruitingNot Applicable

PSMA-PET/CT and genomic alterations for future selection of patients with metastatic castration resistant prostate cancer (mCRPC) for Radium-223 treatment. - The Radium-select study

Start Date12 Mar 2025

Sponsor / Collaborator-

100 Clinical Results associated with Radium Ra-223 Dichloride

100 Translational Medicine associated with Radium Ra-223 Dichloride

100 Patents (Medical) associated with Radium Ra-223 Dichloride

943

Literatures (Medical) associated with Radium Ra-223 Dichloride

01 Jul 2026·CANCER

Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib

Article

Author: Hussain, Arif ; Kyriakopoulos, Christos E. ; Shapiro, Geoffrey I. ; Ajmera, Archana ; Olson, Adam ; Xie, Wanling ; Parikh, Mamta ; Saraiya, Biren ; McKay, Rana R. ; Araneta, Arlene ; Parikh, Rahul ; Folefac, Edmund

Abstract:

Background:

The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.

Methods:

Patients were randomized 1:1 to olaparib plus radium‐223 (arm A) or radium‐223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy–Prostate (FACT‐P) and Brief Pain Inventory (BPI) at baseline and every 12 weeks. Clinically meaningful changes were defined as a ≥10‐point change in FACT‐P total score and a ≥30% or ≥2‐point change in BPI score. Mixed‐effects analysis‐of‐covariance models assessed PRO changes with adjustment for baseline characteristics among patients with baseline and ≥1 postbaseline assessment within 24 weeks.

Results:

Of 114 treated patients, 74 (65%) were evaluable (arm A, n = 40; arm B, n = 34). Baseline characteristics were balanced, with a median age of 70–72 years and Eastern Cooperative Oncology Group performance status of 1 in 60%–62%, prior docetaxel in 50%–55%, >20 BM in 45%–47%, and pain medication use in 60%–72% of patients. No significant differences in FACT‐P total score change was observed at Week 12 (−4.87; 95% CI, −13.4 to 3.62) or Week 24 (1.79; 95% CI, −8.28 to 11.9). BPI pain severity did not differ at Week 12 (0.44; 95% CI, −0.44 to 1.33) or Week 24 (−0.20; 95% CI, −1.32 to 0.93). Arm B showed greater improvement in BPI pain interference at Week 12 (1.09; 95% CI, 0.14 to 2.05), which was not sustained at Week 24.

Conclusions:

The addition of olaparib to radium‐223 was not associated with significant detriment to PROs or pain, which supports the tolerability of this combination.

01 Jul 2026·Clinical and Translational Radiation Oncology

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models

Article

Author: Toner, Aislinn ; Wilson, Melissa LaBonte ; Savage, Kienan I ; Wright, Timothy C ; Dunne, Victoria L ; Prise, Kevin M ; O'Sullivan, Joe M

INTRODUCTION:

Personalised medicine approaches are redefining the therapeutic landscape for men with metastatic castration-resistant prostate cancer (mCRPC). While poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit in patients with BRCA1/2 mutant tumours, the therapeutic efficacy of these inhibitors in Ataxia-telangiectasia mutated (ATM)-mutated prostate cancer patients remains modest, highlighting the need for alternative treatment strategies. This study aimed to elucidate the impact of ATM loss on radiobiological and immune responses to different radiation modalities in prostate cancer models.

METHODS:

Isogenic CRISPR Cas-mediated ATM-deficient and wild-type (WT) cells were treated with X-rays or Radium-223 dichloride (²²³Ra). Cellular radiosensitivity was measured using clonogenic assays and 53BP1 immunofluorescence assessed DNA damage. Cell cycle distribution and apoptosis were analysed by flow cytometry. Innate immune activation was assessed using cGAS immunofluorescence and quantitative PCR of CCL5, CXCL10 and IFIT2.

RESULTS:

²²³Ra significantly increased radiosensitivity in comparison to X-rays which was amplified by ATM loss. ²²³Ra exposure in ATM deficient cells induced significantly greater levels of DNA damage as measured by persistent 53BP1 foci at 24h, distinct G2 accumulation and elevated levels of apoptosis in PC-3 and DU145 ATM-deficient cells in comparison to either X-rays or WT counterparts (p < 0.05). Furthermore, ²²³Ra triggered cGAS positive micronuclei and upregulation of STING driven inflammatory genes, particularly in ATM-deficient cells (p < 0.05).

CONCLUSIONS:

These findings demonstrate that ATM-deficiency enhances radiobiological response and amplifies immune activation to ²²³Ra, supporting further pre-clinical evaluation of ATM loss as a determinant of response and therapeutic target to optimise ²²³Ra based strategies for mCRPC.

20 Jun 2026·JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

Article

Author: Madison, Russell ; Manning, Danielle K. ; Parikh, Rahul ; Kochupurakkal, Bose ; Olson, Adam ; Pasquina, Lincoln W. ; Van Allen, Eliezer ; Gasco, Amaya ; Shapiro, Geoffrey I. ; Ajmera, Archana ; Xie, Wanling ; Saraiya, Biren ; Ivy, Percy ; Childress, Merrida ; Parikh, Mamta ; Araneta, Arlene ; McKay, Rana R. ; Folefac, Edmund ; Jamieson, Christina ; Hussain, Arif ; Kyriakopoulos, Christos E. ; Clifford, Sarah

PURPOSE:

Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223.

PATIENTS AND METHODS:

Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223 (55 kBq/kg intravenous once every 4 weeks × 6 doses) or radium-223. Crossover was allowed at progression. The primary end point was investigator-assessed radiographic progression-free survival (rPFS).

RESULTS:

A total of 120 patients were randomly assigned. Most had prior androgen receptor pathway inhibitor exposure (96%), 52% had received docetaxel, 47% had >20 BM, and 90% received bone-protecting agents. The combination significantly improved rPFS (median 8.9 v 4.7 months; hazard ratio [HR], 0.50 [one-sided 90% CI, 0.35 to 0.70]; one-sided P = .0042). The benefit was most pronounced in patients without prior docetaxel (13.7 v 5.7 months; HR, 0.24 [90% CI, 0.15 to 0.40]) and those with ≤20 BM (13.4 v 4.2 months; HR, 0.21 [90% CI, 0.13 to 0.33]). The 1-year cumulative incidence of symptomatic skeletal-related events was lower with the combination (12.7% v 22.9%). Median overall survival was similar (20.2 v 21.1 months). Grade ≥3 treatment-related adverse events occurred in 56% versus 33% (combination v radium-223), primarily hematologic, including lymphopenia (31% v 9.1%), anemia (22% v 16%), and thrombocytopenia (6.8% v 3.6%).

CONCLUSION:

Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage–targeted strategies in this population.

News (Medical) associated with Radium Ra-223 Dichloride

04 Aug 2026

·www.biospace.com

Archeus Technologies Reconstitutes Advisory Board to Advance Clinical-Stage Radiopharmaceutical Pipeline

Five new advisors, assembled under the leadership of chair Norman LaFrance, M.D., bring decades of clinical, scientific, and industry leadership to Archeus’ radiopharmaceutical programs and development strategy MADISON, Wis.--(BUSINESS WIRE)-- Archeus Technologies , a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers, today announced the reconstitution of its Advisory Board, appointing five leaders with deep expertise across clinical development, drug discovery, and biopharmaceutical leadership. “The Advisory Board has been rebuilt to reflect where Archeus is today — a company with two active Phase 1 programs and a pipeline of novel assets behind them,” said Norman LaFrance, M.D., chair of Archeus’ Advisory Board. “These five advisors were selected because their expertise maps directly to the decisions Archeus is making now — advancing two clinical programs in radiopharmaceutical therapy, deepening a differentiated pipeline, and translating innovative science into proof of concept. Each of them is a recognized leader in their field, and together they represent a meaningful transition in the caliber of expertise Archeus has brought to the table.” “This board reflects the company we are becoming,” said Evan Sengbusch, Ph.D., president and chief executive officer of Archeus Technologies. “We are moving into a more demanding phase of development, and we’re building the leadership around us to match that ambition. The expertise we’ve assembled positions Archeus to accelerate — across the clinic, the pipeline, and the partnerships that will define our next chapter.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The five new members of the Archeus Advisory Board are: Jeremie Calais, M.D., Ph.D., is professor and director of the Clinical Research Program at UCLA’s Ahmanson Translational Theranostics Division, and a faculty member at the Jonsson Comprehensive Cancer Center and the Institute of Urologic Oncology. A leading researcher in prostate cancer imaging and theranostics, he serves as principal investigator of randomized Phase 2 and Phase 3 trials in PSMA PET imaging and PSMA radionuclide therapy. The Ahmanson Translational Theranostics Division submitted, jointly with UCSF, the academic NDA for ⁶⁸Ga-PSMA-11 — the first FDA-approved PSMA PET imaging agent for prostate cancer. Dr. Calais received his M.D. from the University of Paris-Diderot and is board-certified in nuclear medicine in France. Lawrence Fong, M.D., is scientific director of the Immunotherapy Integrated Research Center at Fred Hutch Cancer Center. A physician-scientist focused on cancer immunotherapy, Dr. Fong has contributed to the development of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors, and led clinical trials combining immune checkpoint inhibitors with radiopharmaceuticals including radium-223 and PSMA-lutetium-177. He is a recipient of the National Cancer Institute Outstanding Investigator Award and received his M.D. and completed his fellowship in medical oncology at Stanford University. Marco Gottardis, Ph.D., is the owner of Gottardis Biotech LLC, a biopharmaceutical consultancy, and previously served as vice president of oncology innovation at Janssen Pharmaceuticals (Johnson & Johnson). He spent nine years leading Janssen’s prostate cancer research and development portfolio as vice president and prostate cancer program leader, and 14 years prior in oncology discovery research at Bristol Myers Squibb. He has led teams responsible for advancing development candidates from IND through Phase 2 proof of concept, and contributed to multiple FDA-approved therapies. Dr. Gottardis holds a B.S. in Biology from Columbia University and a Ph.D. in Human Oncology from the University of Wisconsin–Madison. Jonathan Young, Ph.D., most recently served as chief scientific officer of WARF Therapeutics, the Wisconsin Alumni Research Foundation’s drug discovery program. During his eight-year tenure, his team reviewed more than 60 University of Wisconsin–Madison research opportunities and advanced three development candidates to licensing, including WT-7695 (now SKL37321), a CA9 radiopharmaceutical licensed to SK Biopharmaceuticals in November 2025. Earlier, Dr. Young held senior chemistry leadership roles at Regulus Therapeutics, Celgene, and Merck Research Laboratories. He received his Ph.D. in Chemistry from Michigan State University. Stuart Grossman, M.D., is professor of oncology at the Johns Hopkins Kimmel Cancer Center. For the past 22 years, he has served as principal investigator and director of Central Operations for the National Cancer Institute-funded Phase 1/2 brain tumor consortia, including the Adult Brain Tumor Consortium. Dr. Grossman has led many Phase 1, 2, and 3 translational and clinical brain cancer research projects, with expertise in designing and directing large, multicenter, multidisciplinary clinical trial groups — experience directly applicable as Archeus expands its early-phase clinical footprint across multiple programs. He received his M.D. from the University of Rochester School of Medicine and completed his fellowship in medical oncology at the Johns Hopkins University School of Medicine. About Archeus Technologies Archeus Technologies is a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers. Starting with its Phase 1 therapeutic candidate, ARC-706, the company has assembled a growing pipeline of novel RPT agents with the potential to provide curative responses to patients with advanced disease. Archeus is led by an executive team with deep expertise in radiopharmaceutical discovery, isotope chemistry, and clinical translation. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin–Madison (UW), a global leader in radiopharmaceuticals and theranostics, which enables privileged access to leading radiochemistry, imaging, dosimetry, and analytical capabilities to support meaningful progress in this highly technical space. To learn more, visit ArcheusTech.com . Contacts Media Contact Emma Yang Supreme Communications (908) 391-7197 emma.yang@supremecomms.ai

Phase 1Executive ChangeDrug Approval

28 Jul 2026

·www.biospace.com

Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy

Dr. Oliver Sartor brings more than 35 years advancing the clinical development and commercialization of oncology and radiopharmaceuticals Professor Michael Hofman brings more than 20 years pioneering molecular imaging and precision radiotheranostics SHREVEPORT, La., July 28, 2026 (GLOBE NEWSWIRE) -- Starget Pharma Inc. (Starget), a U.S. clinical-stage radiopharmaceutical company, today announced the appointment of Oliver Sartor, MD, and Professor Michael Hofman, MBBS, FRACP, FAANMS to its Scientific Advisory Board (SAB), further strengthening the Company's scientific leadership as it advances multiple radioligand programs toward the clinic from its AI-powered discovery platform. Dr. Sartor and Professor Hofman are internationally recognized leaders in oncology and radiopharmaceutical medicine. Their decades of experience spanning scientific innovation through clinical development have helped establish radioligand therapy as an emerging pillar of cancer treatment. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “We are honored to welcome Oliver and Michael to our Scientific Advisory Board,” said Sigal Kalmanson Cusnir, CEO and Co-Founder of Starget Pharma. “Their deep experience advancing radioligand therapies into clinical practice will help shape our development strategy as we further advance our next-generation radioligand pipeline.” Dr. Sartor added, “Starget’s platform combines artificial intelligence with advanced peptide engineering to design radioligands with the potential to improve tumor targeting and pharmacologic performance. I look forward to working with the team to help expand the reach of radioligand therapy across a broader range of cancer targets.” Professor Hofman added, “Radiotheranostics offers a unique advantage in drug development by showing where a radioligand goes before treatment. Starget’s approach using insights from imaging to inform AI-driven optimization has the potential to accelerate the development of more effective radiopharmaceuticals, and I look forward to helping advance that vision.” Oliver Sartor, MD is an internationally recognized medical oncologist and one of the world’s leading experts in prostate cancer and radiopharmaceutical therapies. He serves as Director of the Transformational Prostate Cancer Research Center at East Jefferson General Hospital Cancer Center and previously served as Director of Radiopharmaceutical Clinical Trials at Mayo Clinic. He has led numerous landmark clinical trials that resulted in the approval of transformative therapies, including Xofigo ® (radium-223), Pluvicto ® (¹⁷⁷Lu-PSMA-617), Jevtana ® (cabazitaxel), and Quadramet ® (samarium-153). Dr. Sartor has authored more than 600 peer-reviewed publications. Professor Michael Hofman, MBBS, FRACP, FAANMS, is a globally recognized nuclear medicine physician and physician-scientist and a pioneer in molecular imaging and theranostics. Serving as an independent advisor, he is based at Peter MacCallum Cancer Centre and the University of Melbourne, where he led landmark clinical trials, including proPSMA, TheraP, UpFrontPSMA and PRIMARY2, that have helped establish PSMA imaging and radioligand therapy as standards of care for prostate cancer. His research spans radiopharmaceutical discovery, clinical translation and imaging biomarkers, with publications in leading medical journals including The Lancet . About Starget Pharma Inc. Starget Pharma is a clinical-stage radiopharmaceutical company developing next-generation peptide radioligand therapies for cancer, with operations in the U.S. and Israel. The Company’s AI-powered platform integrates computational peptide design, theranostic imaging, and biological feedback to accelerate the discovery and optimization of radioligands with the potential to improve tumor targeting and pharmacologic performance. Starget Pharma is advancing a wholly owned pipeline of differentiated radioligand therapies across a broad range of cancers, including lead programs targeting SSTR3 and GRPR that are designed to address significant unmet needs with first-in-class and best-in-class potential. Learn more at . Investor Contact Chuck Padala LifeSci Advisors, LLC chuck@lifesciadvisors.com

Executive Change

22 Jul 2026

·www.biospace.com

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC LOS ANGELES--(BUSINESS WIRE)-- $KAPA #Bayer --Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Kairos Pharma’s current programs with ENV-105 include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial for castrate resistant prostate cancer. Last year, Kairos announced positive interim efficacy data from the Phase 2 trial showcasing median progression-free survival was more than 13 months, a significant improvement from standard of care. These data were presented at the 2025 ESMO Congress in Berlin. XOFIGO is the first and only FDA-approved alpha-emitting radiopharmaceutical for mCRPC with symptomatic bone metastases and is currently advancing through additional combination studies, including the Phase III PEACE-3 trial, which demonstrated a 24% reduction in mortality risk when combined with enzalutamide (HR 0.76; p=0.009). “Drug resistance remains one of the greatest challenges in advanced prostate cancer, and XOFIGO, like many standard-of-care therapies, can lose efficacy over time,” said John Yu, M.D., Kairos Pharma Chief Executive Officer. “ENV-105 has already demonstrated the ability to re-sensitize tumors to existing treatments with a strong safety profile, and this collaboration with Bayer represents a major milestone in our mission to deliver more durable and more effective treatment regimens for patients with metastatic prostate cancer.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Previous published work has demonstrated the efficacy of ENV-105 in radiation sensitization in prostate cancer preclinical models. CD105 is upregulated in response to standard androgen receptor inhibition and in responses to ionizing radiation, driving pro-survival BMP-SMAD signaling pathways underlying therapy resistance. Targeting CD105 with ENV-105 re-sensitizes resistant tumors and may extend the duration and depth of response to XOFIGO's targeted alpha therapy. Neil Bhowmick, Ph.D., Chief Scientific Officer and Principal Investigator stated, "CD105's role as a central resistance mechanism validated now across multiple drug classes makes this collaboration scientifically compelling and clinically timely, given XOFIGO's recent Phase III momentum." About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For more information, visit kairospharma.com . CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws. Contacts investors@kairospharma.com

Clinical ResultPhase 2Phase 1Drug ApprovalPhase 3

100 Deals associated with Radium Ra-223 Dichloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Radium Ra-223 Dichloride	V10XX03	DB08913

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	China	Institute For Energy Technology	26 Aug 2020
Bone metastases	European Union	Bayer AG	13 Nov 2013
Bone metastases	Iceland	Bayer AG	13 Nov 2013
Bone metastases	Liechtenstein	Bayer AG	13 Nov 2013
Bone metastases	Norway	Bayer AG	13 Nov 2013
Castration-Resistant Prostatic Cancer	United States	Bayer HealthCare Pharmaceuticals, Inc.	15 May 2013
Castration-Resistant Prostatic Cancer	United States	Bayer Healthcare LLC	15 May 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Phase 3	-	Bayer AG	01 Sep 2023
Metastatic Prostate Carcinoma	Phase 3	-	Bayer AG	01 Sep 2023
Metastatic castration-resistant prostate cancer	Phase 3	China	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	Singapore	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	South Korea	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	Taiwan Province	Bayer AG	26 Mar 2013
Hormone-dependent prostate cancer	Phase 2	Spain	Bayer AG	01 Sep 2026
Metastatic Prostatic Adenocarcinoma	Phase 2	United States	Bayer AG	28 Apr 2022
Metastatic Prostatic Adenocarcinoma	Phase 2	Brazil	Bayer AG	28 Apr 2022
Oligometastatic Prostate Carcinoma	Phase 2	United States	Bayer AG	27 Feb 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04109729 (ASCO2026)	Phase 1	Metastatic castration-resistant prostate cancer	39	radium-223+nivolumab	zsmycgjqbz(ogoirgckrn) = zjmrakujtb nwmbxucpal (oivwublznf ) View more	Positive	29 May 2026
NCT04090398 (ETCTN 10302, ASCO2026)	Phase 2	Metastatic breast cancer HER2-negative	70	Radium-223 dichloride + Paclitaxel	muxxkylfec(ofjhccegvg) = iaxapqqpms ciypjdpcif (bdaxtkeuen ) View more	Negative	29 May 2026
				Paclitaxel	muxxkylfec(ofjhccegvg) = rkqnenohge ciypjdpcif (bdaxtkeuen ) View more
AUA2026	Not Applicable	Metastatic castration-resistant prostate cancer	386	Radium-223 + ADT + Enzalutamide	arddvsjkjx(uqorrgwxck) = xugqypdcec cjrpkxhkrd (dsebhicuib ) View more	Positive	15 May 2026
				Radium-223 + ADT	arddvsjkjx(uqorrgwxck) = hvoabvmkdf cjrpkxhkrd (dsebhicuib ) View more
NCT03317392 (COMRADE, CTgov)	Phase 1/2	Metastasis from malignant tumor of prostate \| Metastatic Prostatic Adenocarcinoma \| Metastatic castration-resistant prostate cancer	132	Computed Tomography+Radium Ra 223 Dichloride+Olaparib (Phase II Arm I (Radium Ra 223 Dichloride, Olaparib))	zymbgeweuh(oqwjpivkop) = crtfmrrlks zkwhbdjcnt (mfiwhdbgjj, oplmoiapho - ntaovtfsdr) View more	-	05 May 2026
				Computed Tomography (Phase II Arm II (Radium Ra 223 Dichloride))	zymbgeweuh(oqwjpivkop) = qtnhjjxsml zkwhbdjcnt (mfiwhdbgjj, lvozgfcgmn - rkgkpfuvin) View more
NCT03361735 (CTgov)	Phase 2	Castration-sensitive prostate cancer \| Metastatic Prostate Carcinoma \| Adenocarcinoma of prostate	25	Radium Ra 223 Dichloride (De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))	akxgjhictd(evnyeyajgg) = vhclxcgpqw zxzyyygofi (fjqeqdoksa, ivukkppbct - fewoamthsz) View more	-	09 Apr 2026
				Radium Ra 223 Dichloride (Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))	akxgjhictd(evnyeyajgg) = gpwihkubeh zxzyyygofi (fjqeqdoksa, tqwbaugomc - szxcnfmmcj) View more
NCT02194842 (PEACE-3 \| EORTC1333, ASCO_GU2026 \| BusinessWire) Manual	Phase 3	Metastatic castration-resistant prostate cancer	446	Enzalutamide + Radium-223	vsxgzsgfts(jmteeffieb) = rqrieewcri euqhsutslx (ymfksrlxna ) View more	Positive	26 Feb 2026
				Enzalutamide	vsxgzsgfts(jmteeffieb) = hnsqwuaouy euqhsutslx (ymfksrlxna ) View more
ASCO_GU2026	Not Applicable	Metastatic castration-resistant prostate cancer	661	Radium-223	hgswkopggw(wnnkckoljc) = faapynpyzz qaysdyqmer (jacvbrglfu, 10.2 - 12.1)	Positive	26 Feb 2026
				Radium-223 (PTEN, TP53, or RB1 alterations)	hgswkopggw(wnnkckoljc) = dvtvexrwpp qaysdyqmer (jacvbrglfu )
NCT02141438 (REASSURE, ASCO_GU2026)	Not Applicable	Metastatic castration-resistant prostate cancer	1,472	Radium-223	ycomhmgosp(cfkoocvqij) = avubcsygxm imrjluuavo (usftwqfrsm, 41.6 - 70.3) View more	Positive	26 Feb 2026
				Radium-223	ycomhmgosp(cfkoocvqij) = ekwbjoefbo imrjluuavo (usftwqfrsm, 22.1 - 32.2) View more
NCT04206319 (ASCO_GU2026 \| ASCO2026)	Phase 2	Non-metastatic prostate cancer	24	Radium-223 (PET-positive bone findings + biochemically recurrent prostate cancer)	vkihmkamcf(areooliuaf) = txingwibab nljfdqxewt (nluetkrqep ) View more	Positive	26 Feb 2026
ASCO_GU2026	Not Applicable	Metastatic castration-resistant prostate cancer	386	Radium-223 + Enzalutamide	tnposndjfh(mktjcrcxih): RR = 3.09, P-Value = 0.0015 View more	Positive	26 Feb 2026
				ADT alone

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis